37.81
+2.57(+7.29%)
Currency In USD
| Previous Close | 35.24 |
| Open | 35.14 |
| Day High | 38.58 |
| Day Low | 34.38 |
| 52-Week High | 63.5 |
| 52-Week Low | 26.2 |
| Volume | 404,609 |
| Average Volume | 715,152 |
| Market Cap | 2.21B |
| PE | -11.46 |
| EPS | -3.3 |
| Moving Average 50 Days | 35.98 |
| Moving Average 200 Days | 44.74 |
| Change | 2.57 |
If you invested $1000 in Apogee Therapeutics, Inc. (APGE) since IPO date, it would be worth $1,780.97 as of May 09, 2025 at a share price of $37.81. Whereas If you bought $1000 worth of Apogee Therapeutics, Inc. (APGE) shares 1 year ago, it would be worth $714.47 as of May 09, 2025 at a share price of $37.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
GlobeNewswire Inc.
May 01, 2025 12:00 PM GMT
SAN FRANCISCO and BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will present at the Bank of America Health Care Conference on Tuesday, May 13, 2025, at 1:40 p.m. P.T.
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
GlobeNewswire Inc.
Mar 03, 2025 11:00 AM GMT
Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately 60-day half-life APG279 (APG777 + APG990) Phase 1b head-to-head study vs. DUPIXENT supported by successful comp
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
GlobeNewswire Inc.
Feb 28, 2025 9:00 PM GMT
Webcast to be held Monday, March 3rd at 8:30 a.m. ETSAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for different